

Special Issue

Novel Antimicrobial Agents for Treatment of *Staphylococcus aureus* Infections

Message from the Guest Editor

Staphylococcus aureus is the leading cause of skin and soft tissue infections in humans. The species may also cause more life-threatening infections, including bloodstream-related infections, endocarditis, and pneumonia. Resistance to several classes of antibiotics continues to increase for *S. aureus*, which has made treatment options for these infections more challenging. It is projected that by 2050 the number of deaths attributed to drug resistant bacteria, including *S. aureus*, will double. Thus, there is an urgent need to develop novel therapies with new mechanisms of action. This Special Issue will focus on new anti-staphylococcal antimicrobials being developed to counter the growing antibiotic resistance problem. Papers describing preliminary or more advanced stages of antimicrobial developments targeting *S. aureus* are encouraged for this Special Issue. Topics can include early in vitro testing, elucidating mechanisms of action, animal studies, and pharmacokinetic or pharmacodynamic analyses. All papers centered on therapies applied to *S. aureus* are welcome for this Special Issue.

Guest Editor

Prof. Dr. William Schwan

Department of Microbiology, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA

Deadline for manuscript submissions

30 June 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/261137

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)